Back to Directory
Re-Aim Therapeutics
Oxford
Founded 2024
Antibody therapies depleting pathogenic T cells for autoimmune disease cure
Re-Aim Therapeutics is a biotechnology company developing antibody-based therapies designed to achieve functional cures for T cell-mediated autoimmune diseases.
The company's approach selectively depletes pathogenic T cell subsets that drive chronic inflammation, using precise targeting of disease-relevant membrane markers only when those cells are in their disease-causing functional state.
Its lead programme targets type-17 T cells, implicated across multiple autoimmune conditions including psoriasis and inflammatory bowel disease.
Company Notes
Member of